These findings reinforce our hypothesis that myeloid cell Jak2/Stat3 signaling is crucial for the development of obesity-induced insulin resistance and inflammation and can be effective therapeutic targets for type 2 diabetes. This evidence concerns the gene JAK2 and type 2 diabetes mellitus.